Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Talal Ben Lulu
Observed names:
Ben-Lulu, Talal,
Talal Ben-Lulu
Institutions:
Ben-Gurion University of the Negev,
Weizmann Institute of Science
Observed institutions:
Ben-Gurion University of the Negev,
Weizmann Institute of Science
ORCID:
0000-0001-5337-9497
Observed ORCID:
0000-0001-5337-9497
OpenAlex ID:
A5027382876
A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
2024
·
Xin Peng
, Xin Huang
, et al.
·
Molecular Cancer
·
37
PDF
Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
2023
·
Ofra Novoplansky
, Avital B. Shnerb
, et al.
·
Molecular Oncology
·
37
PDF
Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
·
Cancer Research
·
27
PDF
Pharmacological activation of SIRT6 suppresses progression of head and neck and esophageal squamous cell carcinoma by modulation of cellular metabolism and protein translation
2025
·
Talal Ben Lulu
, Dinesh Babu Manikandan
, et al.
·
Cell Death and Disease
·
10
PDF
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
2024
·
Ofra Novoplansky
, Sankar Jagadeeshan
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
8
PDF
Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation
2025
·
Shira Sagie
, Tomer Babu
, et al.
·
Cell Reports Medicine
·
4
Supplementary Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
·
1
Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Supplementary Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Supplementary Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Supplementary Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Supplementary Figure from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Supplementary Figure from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Author response for "Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer"
2023
·
Ofra Novoplansky
, Avital B. Shnerb
, et al.
·
Publons reviews and discussion
Author response for "Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer"
2023
·
Ofra Novoplansky
, Avital B. Shnerb
, et al.
·
Publons reviews and discussion
Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023
·
Sankar Jagadeeshan
, Manu Prasad
, et al.
Show more works
View as search
Works count:
23
Citation count:
124
H-index:
5
I10-index:
4
Year
Topic
Type